Effective neuropathic pain relief through sciatic nerve administration of GAD65-expressing rAAV2

Recently, we demonstrated that the administration of GAD65-expressing rAAV2 to DRG attenuates peripheral neuropathy by inducing GABA release in the spinal cord. However, the direct injection to DRG is invasive and may therefore cause nerve injury and other side effects. To circumvent this surgical i...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2009-10, Vol.388 (1), p.73-78
Main Authors: Kim, Jaehyung, Kim, Sung Jin, Lee, Heuiran, Chang, Jin Woo
Format: Article
Language:English
Subjects:
Adenoviridae
Animals
Disease Models, Animal
GABA
GAD65
Ganglia, Spinal
Gene Transfer Techniques
Genetic Therapy - methods
Glutamate Decarboxylase - genetics
Male
Neuralgia - etiology
Neuralgia - therapy
Neuropathic pain
Peripheral Nervous System Diseases - complications
Peripheral Nervous System Diseases - therapy
rAAV2
Rats
Rats, Sprague-Dawley
Sciatic Nerve
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, we demonstrated that the administration of GAD65-expressing rAAV2 to DRG attenuates peripheral neuropathy by inducing GABA release in the spinal cord. However, the direct injection to DRG is invasive and may therefore cause nerve injury and other side effects. To circumvent this surgical intervention, we explored the potential of a much simpler and less invasive route of sciatic nerve administration. Using a neuropathic pain model, we introduced rAAV2-GAD65 through sciatic nerve and examined its therapeutic potency in pain-related behavior tests. Both GFP and GAD65 expression indicated that effective transgene delivery to the DRG can be accomplished via sciatic nerve administration. Equally importantly, the GABA concentration in the spinal cord increased significantly after GAD65 introduction, and pain symptoms were dramatically reduced and persistently controlled. The implication is that the sciatic nerve is a highly promising route for delivering rAAV2 to the DRG, and thus represents a much less invasive, clinically viable gene therapy option.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2009.07.120